Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) was up 2.8% on Thursday . The stock traded as high as $4.06 and last traded at $4.01, with a volume of 273,765 shares traded. The stock had previously closed at $3.90.

Several equities research analysts have weighed in on TTPH shares. Wedbush reaffirmed a “neutral” rating and set a $11.00 price target (up from $8.00) on shares of Tetraphase Pharmaceuticals in a research report on Thursday, May 5th. Gabelli downgraded Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating and set a $7.00 price target on the stock. in a research report on Friday, May 13th. Needham & Company LLC reaffirmed a “hold” rating on shares of Tetraphase Pharmaceuticals in a research report on Saturday, May 14th. Finally, Zacks Investment Research raised Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.75 price target on the stock in a research report on Wednesday, July 6th. Twelve equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $14.85.

The firm’s market cap is $147.16 million. The company’s 50 day moving average price is $4.16 and its 200-day moving average price is $4.47.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.47) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.46) by $0.01. During the same quarter in the prior year, the firm earned ($0.72) EPS. The company earned $1.20 million during the quarter, compared to the consensus estimate of $2.05 million. The business’s revenue for the quarter was down 63.6% compared to the same quarter last year. On average, equities analysts predict that Tetraphase Pharmaceuticals Inc. will post ($1.95) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Tetraphase Pharmaceuticals stock. California Public Employees Retirement System increased its position in Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) by 1,459.3% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 276,000 shares of the biopharmaceutical company’s stock after buying an additional 258,300 shares during the period. California Public Employees Retirement System owned 0.76% of Tetraphase Pharmaceuticals worth $2,768,000 at the end of the most recent reporting period.

Tetraphase Pharmaceuticals, Inc (Tetraphase) is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. It is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.